Silence Therapeutics (SLN) Free Cash Flow (2020 - 2026)
Silence Therapeutics recorded quarterly Free Cash Flow of -$15.6 million in Q1 2026, up 9.68% quarter-over-quarter from -$17.3 million in Q4 2025, and down 26.7% year-over-year from -$21.3 million in Q1 2025.
Silence Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$15.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 26.7% year-over-year to -$15.6 million; the TTM figure through Mar 2026 stood at -$65.6 million (up 8.11% YoY), while the FY2025 annual figure was -$62.3 million, up 8.14% from the prior year.
- Free Cash Flow came in at -$15.6 million for Q1 2026 at Silence Therapeutics, up from -$17.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.1 million in Q2 2024 to a low of -$27.5 million in Q4 2024.
- A 5-year average of -$15.3 million and a median of -$15.6 million in 2026 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 67.54% in 2024 and fell as far as 314.51% in 2024.
- Silence Therapeutics' Free Cash Flow stood at -$16.1 million in 2022, then slumped by 40.46% to -$22.5 million in 2023, then decreased by 22.16% to -$27.5 million in 2024, then soared by 37.29% to -$17.3 million in 2025, then grew by 9.68% to -$15.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$15.6 million, -$17.3 million, and -$10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | -15.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.60 Mn |
| Mar 31, 2026 | -15.60 Mn |
| Dec 31, 2025 | -17.27 Mn |
| Dec 31, 2025 | -17.27 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Jun 30, 2025 | -21.83 Mn |
| Jun 30, 2025 | -21.83 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Dec 31, 2024 | -27.54 Mn |
| Dec 31, 2024 | -27.54 Mn |
| Sep 30, 2024 | -25.48 Mn |
| Sep 30, 2024 | -25.48 Mn |
| Jun 30, 2024 | -6.08 Mn |
| Jun 30, 2024 | -6.08 Mn |
| Mar 31, 2024 | -9.14 Mn |
| Mar 31, 2024 | -9.14 Mn |
| Dec 31, 2023 | -22.55 Mn |
| Dec 31, 2023 | -22.55 Mn |
| Sep 30, 2023 | -6.15 Mn |
| Sep 30, 2023 | -6.15 Mn |
| Jun 30, 2023 | -18.72 Mn |
| Jun 30, 2023 | -18.72 Mn |
| Mar 31, 2023 | -9.27 Mn |
| Mar 31, 2023 | -9.27 Mn |
| Dec 31, 2022 | -16.05 Mn |
| Dec 31, 2022 | -16.05 Mn |
| Sep 30, 2022 | -11.03 Mn |
| Sep 30, 2022 | -11.03 Mn |
| Jun 30, 2022 | -10.37 Mn |
| Jun 30, 2022 | -10.37 Mn |
| Mar 31, 2022 | -19.22 Mn |
| Mar 31, 2022 | -19.22 Mn |
| Dec 31, 2021 | -5.80 Mn |
| Dec 31, 2021 | -5.80 Mn |
| Sep 30, 2021 | -6.34 Mn |
| Sep 30, 2021 | -6.34 Mn |
| Jun 30, 2021 | 37.00 Mn |
| Jun 30, 2021 | 37.00 Mn |
| Mar 31, 2021 | -16.66 Mn |
| Mar 31, 2021 | -16.66 Mn |
| Dec 31, 2020 | -8.37 Mn |
| Dec 31, 2020 | -8.37 Mn |
| Sep 30, 2020 | -7.98 Mn |
| Sep 30, 2020 | -7.98 Mn |